253 related articles for article (PubMed ID: 21990321)
21. Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells.
Castillo J; Erroba E; Perugorría MJ; Santamaría M; Lee DC; Prieto J; Avila MA; Berasain C
Cancer Res; 2006 Jun; 66(12):6129-38. PubMed ID: 16778186
[TBL] [Abstract][Full Text] [Related]
22. Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells.
Urbanik T; Köhler BC; Boger RJ; Wörns MA; Heeger S; Otto G; Hövelmeyer N; Galle PR; Schuchmann M; Waisman A; Schulze-Bergkamen H
Int J Oncol; 2011 Jan; 38(1):121-31. PubMed ID: 21109933
[TBL] [Abstract][Full Text] [Related]
23. The role of N-acetylglucosaminyltransferases V in the malignancy of human hepatocellular carcinoma.
Wei T; Liu Q; He F; Zhu W; Hu L; Guo L; Zhang J
Exp Mol Pathol; 2012 Aug; 93(1):8-17. PubMed ID: 22537550
[TBL] [Abstract][Full Text] [Related]
24. Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice.
Zhang W; Sun HC; Wang WQ; Zhang QB; Zhuang PY; Xiong YQ; Zhu XD; Xu HX; Kong LQ; Wu WZ; Wang L; Song TQ; Li Q; Tang ZY
Gastroenterology; 2012 Dec; 143(6):1641-1649.e5. PubMed ID: 22922424
[TBL] [Abstract][Full Text] [Related]
25. Suppression of TG-interacting factor sensitizes arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells.
Liu ZM; Tseng JT; Hong DY; Huang HS
Biochem J; 2011 Sep; 438(2):349-58. PubMed ID: 21649584
[TBL] [Abstract][Full Text] [Related]
26. Aspartyl-(asparaginyl)-beta-hydroxylase regulates hepatocellular carcinoma invasiveness.
de la Monte SM; Tamaki S; Cantarini MC; Ince N; Wiedmann M; Carter JJ; Lahousse SA; Califano S; Maeda T; Ueno T; D'Errico A; Trevisani F; Wands JR
J Hepatol; 2006 May; 44(5):971-83. PubMed ID: 16564107
[TBL] [Abstract][Full Text] [Related]
27. Cimetidine inhibits epidermal growth factor-induced cell signaling.
Fujikawa T; Shiraha H; Nakanishi Y; Takaoka N; Ueda N; Suzuki M; Shiratori Y
J Gastroenterol Hepatol; 2007 Mar; 22(3):436-43. PubMed ID: 17295779
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of pyruvate kinase M2 isoform inhibits cell motility in hepatocellular carcinoma cells.
Chen YL; Song JJ; Chen XC; Xu W; Zhi Q; Liu YP; Xu HZ; Pan JS; Ren JL; Guleng B
World J Gastroenterol; 2015 Aug; 21(30):9093-102. PubMed ID: 26290635
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of a novel activator of PAK4, the CDK5 kinase-associated protein CDK5RAP3, promotes hepatocellular carcinoma metastasis.
Mak GW; Chan MM; Leong VY; Lee JM; Yau TO; Ng IO; Ching YP
Cancer Res; 2011 Apr; 71(8):2949-58. PubMed ID: 21385901
[TBL] [Abstract][Full Text] [Related]
30. Tiam1 is associated with hepatocellular carcinoma metastasis.
Huang J; Ye X; Guan J; Chen B; Li Q; Zheng X; Liu L; Wang S; Ding Y; Ding Y; Chen L
Int J Cancer; 2013 Jan; 132(1):90-100. PubMed ID: 22573407
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of invasion and metastasis of hepatocellular carcinoma cells via targeting RhoC in vitro and in vivo.
Wang W; Wu F; Fang F; Tao Y; Yang L
Clin Cancer Res; 2008 Nov; 14(21):6804-12. PubMed ID: 18980974
[TBL] [Abstract][Full Text] [Related]
32. Type 2 diabetes mellitus facilitates endometrial hyperplasia progression by activating the proliferative function of mucin O-glycosylating enzyme GALNT2.
Zhou X; Xu Y; Yin D; Zhao F; Hao Z; Zhong Y; Zhang J; Zhang B; Yin X
Biomed Pharmacother; 2020 Nov; 131():110764. PubMed ID: 33152927
[TBL] [Abstract][Full Text] [Related]
33. GALNT2 suppresses malignant phenotypes through IGF-1 receptor and predicts favorable prognosis in neuroblastoma.
Ho WL; Chou CH; Jeng YM; Lu MY; Yang YL; Jou ST; Lin DT; Chang HH; Lin KH; Hsu WM; Huang MC
Oncotarget; 2014 Dec; 5(23):12247-59. PubMed ID: 25362349
[TBL] [Abstract][Full Text] [Related]
34. RhoE is frequently down-regulated in hepatocellular carcinoma (HCC) and suppresses HCC invasion through antagonizing the Rho/Rho-kinase/myosin phosphatase target pathway.
Ma W; Wong CC; Tung EK; Wong CM; Ng IO
Hepatology; 2013 Jan; 57(1):152-61. PubMed ID: 22829315
[TBL] [Abstract][Full Text] [Related]
35. Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.
Blivet-Van Eggelpoël MJ; Chettouh H; Fartoux L; Aoudjehane L; Barbu V; Rey C; Priam S; Housset C; Rosmorduc O; Desbois-Mouthon C
J Hepatol; 2012 Jul; 57(1):108-15. PubMed ID: 22414764
[TBL] [Abstract][Full Text] [Related]
36. Epidermal growth factor receptor expression and gene copy number in fibrolamellar hepatocellular carcinoma.
Buckley AF; Burgart LJ; Kakar S
Hum Pathol; 2006 Apr; 37(4):410-4. PubMed ID: 16564914
[TBL] [Abstract][Full Text] [Related]
37. DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
Mamoune A; Kassis J; Kharait S; Kloeker S; Manos E; Jones DA; Wells A
Exp Cell Res; 2004 Sep; 299(1):91-100. PubMed ID: 15302576
[TBL] [Abstract][Full Text] [Related]
38. Diacylglycerol kinase alpha enhances hepatocellular carcinoma progression by activation of Ras-Raf-MEK-ERK pathway.
Takeishi K; Taketomi A; Shirabe K; Toshima T; Motomura T; Ikegami T; Yoshizumi T; Sakane F; Maehara Y
J Hepatol; 2012 Jul; 57(1):77-83. PubMed ID: 22425622
[TBL] [Abstract][Full Text] [Related]
39. The activation of MEK/ERK signaling pathway by bone morphogenetic protein 4 to increase hepatocellular carcinoma cell proliferation and migration.
Chiu CY; Kuo KK; Kuo TL; Lee KT; Cheng KH
Mol Cancer Res; 2012 Mar; 10(3):415-27. PubMed ID: 22241220
[TBL] [Abstract][Full Text] [Related]
40. Dissecting the effect of targeting the epidermal growth factor receptor on TGF-β-induced-apoptosis in human hepatocellular carcinoma cells.
Caja L; Sancho P; Bertran E; Fabregat I
J Hepatol; 2011 Aug; 55(2):351-8. PubMed ID: 21147185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
